Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;27(3):295-300.
doi: 10.1007/s00345-009-0395-z. Epub 2009 Mar 7.

Economic aspects of bladder cancer: what are the benefits and costs?

K D Sievert  1 , B Amend, U Nagele, D Schilling, J Bedke, M Horstmann, J Hennenlotter, S Kruck, A Stenzl
Affiliations
Free PMC article
Review

Economic aspects of bladder cancer: what are the benefits and costs?

K D Sievert et al. World J Urol. 2009 Jun.
Free PMC article

Abstract

Objective: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate and ongoing invasive monitoring requirement are the key contributors to the economic and human toll of this disease. The purpose of this paper was to utilize the recent literature to identify opportunities for improving the benefits and costs of BC care.

Methods: A PubMed search was performed of recent publications concerning (BC) cost-effectiveness. We reviewed studies, reviews, opinion papers and cost-effectiveness analyses, focusing primarily on non-muscle-invasive bladder cancer (Ta/T1; NMIBC).

Results: New diagnostic tools such as urine markers may assist in more cost-effectively detecting BC at an earlier stage, however, these markers cannot replace the cystoscopy, which is the current standard of care. A photodynamic diagnostic tool (PDD) using hexylaminolevulinate (Hexvix) enhances tumor visibility and improves transurethral resection of bladder cancer (TURB) results, potentially reducing recurrence rates and lowering treatment costs. While the importance of BC research has been acknowledged, research investment has been continuously reduced during the last 5 years.

Conclusions: The economic burden of BC is well-characterized in the literature. This study suggests that new technologies (i.e., urine-based tests, PDD) and therapeutic regimes (intravesical chemotherapy, adjuvant immunotherapy) have significant potential to improve the diagnosis, treatment and on-going monitoring of BC patients, with potential improvements in clinical outcomes and concurrent cost-savings. A renewed interest and investment in BC research are required to ensure future advancements.

PubMed Disclaimer

References

    1. Miller BA, Kolonel LN, Bernstein L et al (1996) Racial/ethnic patterns of cancer in the United States 1988–1992, National Cancer Institute. NIH Pub. No. 96-4104, Bethesda
    1. None
    2. Ferlay J, Parkin DM, Pisani P (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. IARC Press, Lyon
    1. American Cancer Society Cancer facts & figures. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed 20 March 2007
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S1078-1439(99)00052-6', 'is_inner': False, 'url': 'https://doi.org/10.1016/s1078-1439(99)00052-6'}, {'type': 'PubMed', 'value': '10765013', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10765013/'}]}
    2. Han M, Schoenberg MP (2000) The use of molecular diagnostics in bladder cancer. Urol Oncol 5:87–92. doi:10.1016/S1078-1439(99)00052-6 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2165/00019053-200321180-00003', 'is_inner': False, 'url': 'https://doi.org/10.2165/00019053-200321180-00003'}, {'type': 'PubMed', 'value': '14750899', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14750899/'}]}
    2. Botteman MF, Pashos CL, Redaelli A et al (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21:1315–1330. doi:10.2165/00019053-200321180-00003 - PubMed

MeSH terms